mk-3168
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02169973)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)C(=O)[C@H]1C[C@@H]1c1ccc(-c2ncn(C)c2Sc2ccc(Cl)cn2)cc1- Mol. weight
- 412.95 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Imaging
- 11-carbon
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2386558 ↗
Also known as
- mk-3168
- mk-3168
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05065541 | Phase 1 | Sep 24, 2021 | Bristol-Myers Squibb, Celgene |
| NCT04404712 | Early Phase 1 (Phase 1) | Aug 1, 2020 | Yale University |
| NCT02169973 | Phase 1 | Feb 1, 2014 | Johnson and Johnson |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2021 |
| Celgene | For profit | 1 | 1 | 1 | 2021 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2014 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1